🧫
Arketamine (R-ketamine) preliminary efficacy study
active
experiment
Created: 2026-04-10T22:47:07
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-eb39102b-b1e5-471a-8338-e186c52c1501
🧫 Experiment Protocol
Clinicaltreatment-resistant depressionTRD patientsproposed
Preliminary clinical investigation of arketamine (R-ketamine) as a potential improvement over racemic ketamine and esketamine for treatment-resistant depression. This early-phase study examined the R-enantiomer of ketamine, which preliminary data suggested might offer advantages including longer-lasting antidepressant effects, reduced psychomotor adverse effects, and lower potential for substance abuse. The research compared the efficacy, safety, and tolerability profile of arketamine against established ketamine formulations, with particular attention to psychotomimetic side effects and abuse liability that are concerns with current ketamine treatments.
PRIMARY OUTCOME
antidepressant efficacy with improved side effect profile
EXPECTED OUTCOMES
Longer-lasting antidepressant effects with fewer psychomotor side effects and lower abuse potential
SUCCESS CRITERIA
Superior or equivalent antidepressant efficacy with improved tolerability profile compared to existing ketamine formulations
PROTOCOL
Administration of arketamine with comparison to ketamine/esketamine for efficacy and adverse effects
Source: PMID 41935374 ↗
🧫 Experiment Extras
PATHWAY
NMDA receptor signaling
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.